Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer

AHS Cancer Control Alberta

Status and phase: Completed; Phase 2

Conditions: Small Cell Carcinoma; Lung Neoplasm

Treatments: Radiation: Hypofractionated Chest Radiotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT00907569

24762

Details and patient eligibility

About

It is accepted that giving higher doses of chest radiation in as short a time span as possible improves chances of cure. In this study, the investigators propose to give an increased dose of chest radiotherapy for limited stage small cell lung cancer patients using a strategy of giving a slightly higher daily dose of radiotherapy than normal. The investigators hypothesize that our proposed chest radiotherapy dose will improve 2-year overall survival rates in patients with limited stage small cell lung cancer.

Full description

The ideal chest radiotherapy dose/fractionation scheme for limited stage small cell lung cancer is undefined. Strategies of radiotherapy dose intensification with minimization of overall treatment time are felt to improve cure rates for LS-SCLC. Hypofractionation (giving higher than standard daily doses) facilitates both of these goals. In this study, we propose to use a dose escalated hypofractionated regimen of chest radiotherapy for patients with LS-SCLC.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• limited stage small cell lung cancer
• adequate pulmonary function test (FEV1 >1.0 L, DLCO >50%)
• signed study consent
• age at least 18 years
• Karnofsky performance status as least 70%
• eligible to receive standard concurrent small cell cancer chemotherapy

Exclusion criteria

• extensive stage disease
• mixed non small cell and small cell histology
• inadequate pulmonary function tests
• not eligible for concurrent chemotherapy
• subtotal or total tumor resection
• previous chest/neck radiotherapy
• prior or concurrent malignancy except non-melanomatous skin unless disease free for last 5 years
• pregnant
• prior chemotherapy for another malignancy
• patients with myocardial infarction within the preceding 6 months of symptomatic heart disease, including, angina, congestive heart failure, uncontrolled arrhythmias

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)